Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Nov. 30, 2020	Nov. 30, 2019
Cash flows from operating activities:
Net income (loss)	$ 14,890	$ (8,169)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	8,224	9,229
Amortization of debt discount	508	617
Bad debt (recovery) expense	(385)	303
Reduction in the carrying amount of the right of use asset	836	668
Loss (gain) on forward contracts	61	(347)
Equity in income of equity investees	(4,506)	(3,672)
Distribution of income from equity investees	4,248	4,169
Deferred income tax expense (benefit)	4,187	(338)
Non-cash compensation adjustment	(455)	(51)
Stock based compensation expense	1,454	1,816
Gain on sale of property, plant, and equipment		(3,788)
Changes in operating assets and liabilities:
Accounts receivable	(78,692)	(20,880)
Inventory	(31,406)	(9,353)
Receivables from vendors	(19)	790
Prepaid expenses and other	(6,465)	528
Investment securities-trading	455	304
Accounts payable, accrued expenses, accrued sales incentives, contract liabilities, and other liabilities	83,049	3,379
Income taxes payable	1,388	908
Net cash used in operating activities	(2,628)	(23,887)
Cash flows from investing activities:
Purchases of property, plant, and equipment	(3,510)	(2,192)
Purchase of acquired business, less cash received	(11,000)
Proceeds from sale of property, plant, and equipment		11,951
Net cash (used in) provided by investing activities	(14,510)	9,759
Cash flows from financing activities:
Principal payments on finance lease obligation	(470)	(477)
Repayment of bank obligations	(20,375)	(9,046)
Borrowings on bank obligations	20,000
Deferred financing costs	(260)
Settlement of restricted stock units	(575)
Purchase of treasury stock		(2,040)
Net cash used in financing activities	(1,680)	(11,563)
Effect of exchange rate changes on cash	2,730	(389)
Net decrease in cash and cash equivalents	(16,088)	(26,080)
Cash and cash equivalents at beginning of period	37,425	58,236
Cash and cash equivalents at end of period	$ 21,337	$ 32,156